# Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

> **NCT00288236** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 368 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Rimonabant (SR141716)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00288236
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2009-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288236, "Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00288236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*